Looks like they are getting less money up front now. The original deal was for up to US$150 million in upfront and milestone payments prior to product launch but that has been reduced to US$112.5 million. Though it is good that they feel confident to move forward with the program, and that Grünenthal are sticking around.
Ann: Mesoblast Update on Chronic Low Back Pain Program, page-4
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
-0.040(3.74%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | $1.03 | $1.446M | 1.395M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 345059 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 3799 | 1 |
View Market Depth
| Last trade - 10.19am 30/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |